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Purpose/Objective: Radiation-induced lung injury (RILI) is the most 
common side effect after radiation therapy for lung cancer. It is well 
known that the radiological finding of RILI is not always associated 
with the clinical manifestation of pneumonitis, and it is also not clear 
if it correlates with a decrease of patient's pulmonary function. In this 
study, we analyzed the predictive value of dosimetric parameters and 
Pulmonary Function Tests (PFTs), and their correlation with the 
radiological incidence of radiation-induced lung injury (RILI).  
Materials and Methods: Data from patients with non-small cell lung 
cancer (NSCLC), stage I-IIIB, treated with (chemo)-radiation in our 
Institution were analyzed. Eligibility criteria were: presence of visible 
tumor on a diagnostic chest CT scan, availability of CT scans before 
irradiation and at 3–6 months follow-up, baseline PFTs, with at least 
forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), 
total lung capacity (TLC), functional residual capacity (FRC) and vital 
capacity (VC) at 2–4 months follow-up. 
Results: Data from 68 patients treated from 2005 to 2012 were 
analyzed. The worsening of pulmonary function was evaluated 
comparing PFTs performed before and after radiotherapy. We tested 
the difference of percentage of predicted value of all the parameters 
and we obtained statistically significant results for Functional Residual 
Capacity (FRC), Total Lung Capacity (TLC), Vital Capacity (VC) and 
Functional Vital Capacity (FVC). Thirty-nine patients (57,4%) 
developed radiation-induced changes in lung tissue. Eighteen patients 
(26.6%) experienced a radiologically defined RILI associated to a 
worsening of respiratory performance. Nevertheless, these patients 
did not show the signs and symptoms of radiation pneumonitis, nor did 
their respiratory impairment interfere with the activities of daily 
living.  The remaining 19 patients (28.0%) had a post-treatment 
radiological diagnosis of RILI without any respiratory impairment 
during and/or post treatment. Two patients showed clinical signs of 
pneumonitis with only one of them experiencing a worsening of PFTs. 
Logistic regression was performed to verify whether the commonly 
used lung dosimetric constraints could be predictive of RILI. MLD was 
found to be the strongest predictor of RILI (Odds Ratio:1.19; 95% CI: 
1.04 – 1.35; p: 0.009), but even V20, V30, V5, ipsilateral V20 proved 





Conclusions: Our study confirmed the important role of dosimetric 
parameters for the prediction of lung toxicity. It also proved that the 
radiological finding of RILI does not necessarily correlate with a 
worsening of the patient's respiratory performance, especially when 
treatment planning has been performed complying with the lung 
dosimetric constraints.  
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Purpose/Objective: Because small-cell lung cancer has a short 
doubling time, clinicians strive to obtain a diagnosis as soon as 
possible. We investigated the value of a short diagnostic process in a 
prospectively collected cohort of SCLC patients.  
Materials and Methods: Analysis of patients in our prospective 
database with stage I-III SCLC referred for concurrent chemo-
radiotherapy. Standard treatment was 45 Gy in 1.5 Gy fractions twice 
daily concurrently with carboplatin-etoposide, followed by 
prophylactic cranial irradiation (PCI) in case of non-progression. 
Survival was calculated from pathologic diagnosis (Kaplan-Meier 
method). Diagnostic delay was defined as the time between the first 
report of suspicious findings on imaging and the date of pathological 
verification of SCLC status. 
Results: 73 patients were included in the present analysis. Median 
overall survival was 20 months (95% CI 17.8-22.2 months), 2-year 
survival 38%. Median time between first imaging and pathology was 
19±64 days (range -1-505 days). Median time between pathology and 
start of chemotherapy was 13±10 days (range 0-47 days). In 
multivariate Cox regression analysis including WHO-PS, age, gender, 
LDH, PCI, SER, Gross Tumor Volume (GTV) and stage only the 
diagnostic delay significantly impacted overall survival (p=0.018). The 
hazard ratio for death per week delay was 1.04, amounting to a 
hazard ratio of 1.18 per month (28 days) delay. The time between 
pathology date and start of chemotherapy did not significantly impact 
overall survival in this cohort. 
Conclusions: In this series of stage I-III small cell lung cancer treated 
with concurrent chemo-radiation, diagnostic delay is an independent 
risk factor for stage I-III SCLC.  
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Purpose/Objective: Tumor behavior and treatment outcome of 
subgroups of non-small cell lung carcinoma (NSCLC) patients mainly 
depend on histology. In the present study, differences in glucose 
metabolism between adeno- and squamous cell NSCLCs were 
quantified using the hypoxia and glycolysis-related markers GLUT1, 
CAIX, MCT1, MCT4, vascular density, as well as 18FDG-PET imaging in 
curatively resected NSCLC patients. The relevance of these metabolic 
markers for disease-free survival (DFS) were analyzed. 
Materials and Methods: In 111 patients, pre-treatment 18FDG-uptake 
was quantified by calculating SUVmax and TLGmax. Metabolic marker 
expression, measured by immunofluorescent staining (protein) and 
qPCR (mRNA), and vascular density were determined in 90 fresh 
frozen resection specimens. Patients were retrospectively evaluated 
for DFS. 
Results: mRNA and protein expression of metabolic markers, with the 
exception of MCT4, and 18FDG-uptake were higher in squamous cell 
carcinomas than in adenocarcinomas, whereas adenocarcinomas were 
better vascularized. Adenocarcinomas had a worse DFS compared to 
squamous cell carcinomas (p=0.016) based on the potential to 
metastasize. High glucose consumption, as assessed by GLUT1 mRNA, 
SUVmax or TLGmax, was associated with a worse DFS in only 
adenocarcinomas.  
Conclusions: Our findings indicate that adenocarcinomas exhibit 
glycolysis under normoxic conditions close to the vessels, whereas 
squamous cell carcinomas are exposed to diffusion-limited hypoxia 
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resulting in a very high anaerobic glycolytic rate. Despite the fact that 
squamous cell carcinomas have a higher 18FDG-uptake, in general 
regarded as a poor prognostic factor, adenocarcinomas had a higher 
metastatic potential and a worse DFS. Therefore, the prognostic 
potential of 18FDG-PET should be interpreted in relation to histology. 
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Purpose/Objective: Treatment policy of inoperable or irresectable 
NSCLC (inop/irresNSCLC) in our department is consistant from 1995 
and onwards and has been guided by results of several subsequent 
EORTC studies (08844,08912,08972). Cc RT to a dose of 66 Gy/24 fx 
/2,75 Gy/33 days was combined with daily administration of cisplatin 
6mg/m2 1-2 hours before RT (total planned dose 144 mg/ m²) in 
patients with inop or irres disease (ccRCT). Patients were restaged 
and a resection (S) was considered in case of downstaging and strong 
indication or evidence of residual tumor, if radical S by lobectomy 
seemed feasible. Results of ccRCT from 1995-2004 were analysed and 
reported before. The 5 yr overall survival (OS) was 15%, the 5 yr local 
control rate (LCR) was 46 %. PET-staging was gradually introduced in 
our clinic in 2004 and became a standard staging procedure end of 
2006. 
The aim of the present study is to analyse the influence of PET staging 
on treatment results, and to check if our treatment is still appropiate 
in PET staged pts with inop/irresNSCLC. 
Materials and Methods: From2005-2012 136 pts were treated with cc 
RCT or RT. Eligibility criteria: biopsy proven irres or inop NSCLC not 
eligible for stereotactic radiotherapy, clinical and radiological 
suspicion for malignancy, FeV1>1 l, DLCO≥40%, adequate renal, 
haematological and pulmonary function (FeV1≥30 %). Chemotherapy 
was given in 118 pts and consisted of cisplatin 6 mg/m² in 112 pts (in 
6 pts preceded and in one patient followed by 2 courses of standard 
dose platinum containing chemotherapy, SDPtCT). 6 pts received 2 
courses of SDPtCT before RT. Radiotherapy was given by a conformal 
technique in all pts, elective treatment was omitted. The dose was 
defined according to the ICRU50 report. Dose constraints: max dose to 
spinal cord: 50 Gy/2 Gy or equivalent dose, MLD ≤20%, V20 ≤ 40%, 
V35oes ≤65%, max heart dose 40Gy (whole heart) or 50 Gy to 2/3 of 
the heart. Surgery was performed in 11 pts. 
Results: Stage (TNM2007) I, II, III, VI:12,10,101 (74,3%), 4 pts (solitary 
brain metastasis), unknown 9 pts. PET staging: 124 pts. Histology in 
128 pts: scc: 42pts, adenoca: 17pts, large cell undifferentiated ca: 60 
pts, malignant ca nos: 9 pts. Result in pts without histological 
diagnosis was equal to result in other pts. OS: The 1,2 and 5yr 
actuarial OS was 86%, 59% and 31% respectively (resp), mean S 49 
months (m) (95 % CI 38-62 m), median 33m. The 1, 2 and 5 yr LCR was 
83%, 69% and 51%. Mean and median follow-up period was 20 and 15m 
resp., (1,7-88). Late toxicity gr 1,2, 3,4 was present in 3,1,7 and 2 pts 
resp. Two pts died of complications. 
Results of S: lobectomy 10x, bilobectomy 1x. R0:9x, R1:1x, 
irresectable 1x. 
  
Conclusions: Selection of pts with inop/irres NSCLC by staging with 
PET-CT scan before ccRCT consisting of low dose cisplatin 6 mg/ m² 
given cc with radiotherapy 66 Gy/24 fx/33 days leads to an impressive 
increase in 5 yr OS(15to 31%) with similar LC 46-51%). The results are 
comparable with results of combined modality treatment with full 
dose RCT but with less toxicity. 
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Purpose/Objective: To retrospectively assess treatment outcome, and 
toxicity after a moderately escalated hypofractionated radiotherapy 
delivered with Helical Tomotherapy (HT) in locally advanced stage III 
inoperable non-small cell lung cancer (NSCLC) combined with 
sequential or concurrent chemotherapy. 
Materials and Methods: Sixty-one eligible patients were treated with 
combined platinum-based chemotherapy associated with a moderately 
escalated hypofractionated radiation course delivered with HT. The 
treatment schedule consisted of 30 daily fractions ranging from 2.25 
to 2.28 Gy each up to a total dose of 67.5-68.4 Gy to the gross tumour 
volume considered as the primary site and clinically proven nodal 
regions, without elective nodal irradiation. Applying a/bratio of 10, 
the corresponding normalized total dose at 2 Gy per fraction (NTD2) 
was 68.9-70 Gy. Overall survival and local control were assessed as 
well as acute and late toxicity using National Cancer Institute 
Common Terminology Criteria and Adverse Events (CTCAE) version 
3.0. 
Results: No Grade≥ 4 acute and late toxicity was reported. Acute 
Grade 3 treatment-related pneumonitis was detected in 12% of 
patients. Two patients, both receiving the concurrent 
schedule,developed a Grade 3 acute esophagitis. The overall 
incidence of late Grade 3 lung toxicity was 7%. No patients 
experienced a Grade 3 late esophageal toxicity. After a median 
follow-up of 25 months (range, 6-40 months), 2-year local control and 
overall survival rates were 65% and 53% for all patients, 30% of whom 
were stage IIIB. The same features for patients who received 
concurrent chemoradiation were 72% and 56%, respectively.  
Conclusions: Our findings show that a moderately hypofractionated 
radiation course delivered with HT is a feasible treatment option for 
patients with inoperable locally advanced NSCLC receiving 
chemotherapy (sequentially or concurrently). Hypofractionated 
radiotherapy with a dedicated technique allows safely dose 
escalation, minimizing the effect of tumor repopulation that may 
occur with prolonged treatment time. 
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